

SALARIUS PHARMACEUTICALS, INC.
2450 Holcombe Blvd., Suite X
Houston, Texas 77021

August 12, 2022

VIA EDGAR

Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Re: **Salarius Pharmaceuticals, Inc.**
Registration Statement on Form S-3
Filed August 5, 2022
File No. 333-266589
Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Salarius Pharmaceuticals, Inc., a Delaware corporation, hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-266589) and declare the Registration Statement effective as of August 16, 2022, at 4:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.

Please contact the undersigned at (832) 834-6992, or Stephen Nicolai of Hogan Lovells US LLP at (267) 675-4642 with any questions. Also, please notify Mr. Nicolai when this request for acceleration has been granted.

Very truly yours,
SALARIUS PHARMACEUTICALS, INC.

By: /s/ Mark J. Rosenblum
Name: Mark J. Rosenblum
Title: Chief Financial Officer

cc: Stephen Nicolai, *Hogan Lovells US LLP*